<?xml version="1.0" encoding="UTF-8"?>
<p id="Par4">Indefinite treatment duration is suggested for patients with chronic hepatitis B (CHB) and advanced liver cirrhosis, but also in asymptomatic, non viremic patients, as well as sometimes in HBsAg negative patients, as an HBV infection exacerbation prophylaxis, during immunosuppressive therapy to treat malignancies, haematological and rheumatological diseases
 <sup>
  <xref ref-type="bibr" rid="CR5">5</xref>
 </sup>. In patients with negative HBV-DNA and with HBsAg loss, first generation NAs such as lamivudine are still used for HBV reactivation prophylaxis
 <sup>
  <xref ref-type="bibr" rid="CR6">6</xref>
 </sup>.
</p>
